March 6, 2018 / 12:16 PM / a year ago

FDA approves new dosing for Bristol-Myers Squibb's Opdivo

March 6 (Reuters) - Bristol-Myers Squibb Co said on Tuesday the U.S. Food and Drug Administration had approved a new dosing schedule for its drug, Opdivo, across a number of cancers the drug is already approved to treat.

The approval was related to a marketing application for an infused 480 mg dose every four weeks.

Opdivo is already approved to treat a number of cancers such as melanoma. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below